SUB

Thermo Fisher Scientific Expands St. Louis Manufacturing for Complex Biologic Treatments

Retrieved on: 
Thursday, October 5, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, SUB, Patient, Thermo, Cancer, Multimedia, Thermo Fisher Scientific, DSM-IV codes, Single-use bioreactor, Vaccine, Pharmaceutical industry, St. Louis

Thermo Fisher Scientific, the world leader in serving science, today expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ranging from cancers to auto immune conditions to rare genetic disorders.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ranging from cancers to auto immune conditions to rare genetic disorders.
  • View the full release here: https://www.businesswire.com/news/home/20231005422767/en/
    Thermo Fisher Scientific expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ranging from cancers to auto immune conditions to rare genetic disorders.
  • (Photo: Business Wire)
    Thermo Fisher made a significant investment since 2021 to add 58,000 square feet of biologics manufacturing space.
  • The expansion adds manufacturing suites that will contain up to four Thermo Scientific™ DynaDrive™ Single-Use Bioreactors (SUB), each of which can process up to 5,000 liters.

Unifor members ratify collective agreement with Ford Motor Company

Retrieved on: 
Sunday, September 24, 2023
Private sector, EV, Unifor National Council 4000, SUB, DC, Ford, History, Quality, Holiday, Retirement, Social justice, Tradesman, Dental care, COLA, Automotive industry, Airline, Pension fund, Health insurance, Dietary supplement, Unifor

TORONTO, Sept. 24, 2023 /CNW/ - Unifor members voted to ratify a new three-year collective agreement with Ford of Canada.

Key Points: 
  • TORONTO, Sept. 24, 2023 /CNW/ - Unifor members voted to ratify a new three-year collective agreement with Ford of Canada.
  • "Our bargaining team showed exceptional leadership and successfully pushed Ford of Canada on every front," said Unifor National President Lana Payne.
  • The newly ratified three-year collective agreement covers more than 5,600 workers at Ford facilities in Canada.
  • Unifor Ford members voted 54% in favour of the new tentative agreement.

Global Single-use Bioprocessing Market Outlook & Forecast 2023-2028: New Product Launches & Increasing Strategic Acquisitions and Collaborations Spearheading Growth and Expansion - ResearchAndMarkets.com

Retrieved on: 
Friday, September 22, 2023
Medical Supplies, Health, Vaccine, Biopharmaceutical, Workflow, Hook effect, SUB, SUT, Stainless steel, Bioreactor, Sterilization, Research and development, Protein, Acquisition, Patent, Investment, Risk, Mab, Quality control, Filtration, Growth, R, Safety, Sut Jhally, Syringe, Fine chemical, Medical device, Research

New Product Launches: Technological advancements have played a pivotal role in the global expansion of single-use bioprocess consumables.

Key Points: 
  • New Product Launches: Technological advancements have played a pivotal role in the global expansion of single-use bioprocess consumables.
  • Increasing Strategic Acquisitions and Collaborations: The strategic acquisition of single-use technology can enhance its adoption across the biopharmaceutical industry.
  • In summary, the single-use bioprocessing market is evolving rapidly, with trends and drivers like new product launches, strategic acquisitions, and growing biomanufacturing capacity fueling its growth and expansion.
  • In 2022, the single-use bioprocessing equipment product type held a larger share of the global single-use bioprocessing market.

Single-use Bioreactors Global Market Report 2022: Increasing Adoption of SUBs Among Small Companies and Startups Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023
Health, Biotechnology, Molecule, CMOS, Business analysis, R, Cros, Laboratory, Vaccine, Submarine, Chapter Five, Growth, Application, Drug discovery, Patent, Buffer, Research, Biosimilar, Biofuel, Antibody, SUB, USD, Investment, GMP, Cell, Fine chemical

The global single-use bioreactors market size is expected to reach USD 12,062.5 million by 2030.

Key Points: 
  • The global single-use bioreactors market size is expected to reach USD 12,062.5 million by 2030.
  • Owing to the rising demand for biopharmaceuticals, coupled with increasing investments in single-use technologies, the market for single-use bioreactors is expected to witness a significant growth throughout the forecast period.
  • Additionally, the single-use bioreactors market is projected to benefit from new opportunities brought on by license termination and emerging markets.
  • Thus, propelling the market growth
    Chapter 5 Single - Use Bioreactors Market: Product Business Analysis
    Chapter 6 Single - Use Bioreactors Market: Type Business Analysis
    Chapter 7 Single - Use Bioreactors Market: Type Of Cell Business Analysis
    Chapter 8 Single - Use Bioreactors Market: Molecule Type Business Analysis
    Chapter 9 Single - Use Bioreactors Market: Application Business Analysis
    Chapter 10 Single - Use Bioreactors Market: Usage Type Business Analysis
    Chapter 11 Single - Use Bioreactors Market: End - Use Business Analysis
    Chapter 12 Single - Use Bioreactors Market: Regional Business Analysis

ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies

Retrieved on: 
Tuesday, January 3, 2023
Partnership, SUB, GMP, Thermo Fisher Scientific, SAN, TMO, Patient, NYSE, Safety, ASLN, Atopic dermatitis, AD, Vaccine, Pharmaceutical industry

ASLAN has developed a high concentration formulation of eblasakimab, allowing up to 400mg eblasakimab to be administered in a single subcutaneous injection and suitable for use with different devices.

Key Points: 
  • ASLAN has developed a high concentration formulation of eblasakimab, allowing up to 400mg eblasakimab to be administered in a single subcutaneous injection and suitable for use with different devices.
  • Thermo Fisher plans to commence manufacturing the new formulation in its commercial-scale Good Manufacturing Practices (GMP) certified manufacturing facilities in January 2023.
  • “Establishing this partnership with Thermo Fisher, a global leader in biologics manufacturing, is an important strategic milestone as we continue to advance the development of eblasakimab towards global Phase 3 clinical trials.
  • The company is also conducting the TREK-DX study to evaluate eblasakimab in adult patients with moderate-to-severe AD who have previously been treated with dupilumab.

VOOPOO Sweeps the Board with Seven Awards at the Ecigclick Vape Awards 2022

Retrieved on: 
Monday, December 19, 2022
ARGUS, VINCI, SUB, Social media, Jet engine, Herbal cigarette, R, Perception, MTL, BEST, TANK, Tobacco

SHENZHEN, China, Dec. 19, 2022 /PRNewswire/ -- On December 14, Ecigclick, one of the biggest and authoritative online global media outlets for vapes, revealed the winners for the Ecigclick Vape Awards 2022. VOOPOO, a leading vape brand, won seven awards, cementing the company's dominant position in the e-cigarette industry.

Key Points: 
  • SHENZHEN, China, Dec. 19, 2022 /PRNewswire/ -- On December 14, Ecigclick, one of the biggest and authoritative online global media outlets for vapes, revealed the winners for the Ecigclick Vape Awards 2022 .
  • VOOPOO , a leading vape brand, won seven awards, cementing the company's dominant position in the e-cigarette industry.
  • Take VOOPOO ARGUS POD , the pod winning the BEST FOR BEGINNERS, as an example; it combines the innovations of VOOPOO towards optimal mouth-to-lung (MTL) vaping.
  • VOOPOO has already released 17 products in 2022, and it is anticipated that in December, VOOPOO will launch two other products.

VOOPOO Sweeps the Board with Seven Awards at the Ecigclick Vape Awards 2022

Retrieved on: 
Monday, December 19, 2022
ARGUS, VINCI, SUB, Social media, Jet engine, Herbal cigarette, R, Perception, MTL, BEST, TANK, Tobacco

SHENZHEN, China, Dec. 19, 2022 /PRNewswire/ -- On December 14, Ecigclick, one of the biggest and authoritative online global media outlets for vapes, revealed the winners for the Ecigclick Vape Awards 2022. VOOPOO, a leading vape brand, won seven awards, cementing the company's dominant position in the e-cigarette industry.

Key Points: 
  • SHENZHEN, China, Dec. 19, 2022 /PRNewswire/ -- On December 14, Ecigclick, one of the biggest and authoritative online global media outlets for vapes, revealed the winners for the Ecigclick Vape Awards 2022 .
  • VOOPOO , a leading vape brand, won seven awards, cementing the company's dominant position in the e-cigarette industry.
  • Take VOOPOO ARGUS POD , the pod winning the BEST FOR BEGINNERS, as an example; it combines the innovations of VOOPOO towards optimal mouth-to-lung (MTL) vaping.
  • VOOPOO has already released 17 products in 2022, and it is anticipated that in December, VOOPOO will launch two other products.

Microbial Fermentation Technology Market Trends/Analysis Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 16, 2022
Biotechnology, Pharmaceutical, Health, Genomatica, Metabolic engineering, SUB, National Biotechnology Research Park, Cargill, CSR, ABEC, CMOS, Cyclone, Agitation, Inactivated vaccine, Tropical cyclone engineering, SWOT, Fermentation, USD, Growth, Biopharmaceutical, Hormone, Fine chemical, Vaccine

The "Microbial Fermentation Technology Market Size, Share & Trends Analysis Report by Application (Antibiotics, Vaccines), by End-use (Biopharmaceutical Companies), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microbial Fermentation Technology Market Size, Share & Trends Analysis Report by Application (Antibiotics, Vaccines), by End-use (Biopharmaceutical Companies), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Since fermentation is observed to be of utmost importance in the manufacturing of biopharmaceuticals, there is also a growing demand for microbial fermentation technology in biopharmaceutical manufacturing.
  • The newly installed solutions are expected to provide a faster turnaround time with high-growth microbial fermentation on large scale.
  • Furthermore, technological advances in microbial fermentation platforms are also expected to supplement the market growth.

Avirmax CMC Inc. Received License for cGMP Gene Therapy Vector Production by the California Department of Public Health

Retrieved on: 
Monday, October 31, 2022
Bayer, HEK293, AAV, Founder CEO, CDMO, California Department, Knowledge, CEO, Sf9, Contract manufacturing organization, CGMP, BHK, Public health, Technology, Drug development, SUB, A-DNA, DNA, DVM, Rita Raave, Therapy, CHO, Vaccine, Fine chemical, San Francisco Bay Area, Genentech

The facility has received cGMP license approval by the California Department of Public Health (CDPH)-Food & Drug Branch, for the production of rAAV drug products for use in clinical investigations.

Key Points: 
  • The facility has received cGMP license approval by the California Department of Public Health (CDPH)-Food & Drug Branch, for the production of rAAV drug products for use in clinical investigations.
  • The new cGMP facility will support us to deliver high yield and quality vectors efficiently, timely and cost effectively
    The new 20,000 sq.ft.
  • Production scales at 50L, 200L and 1000L, are available to customers depending on their clinical trial size and dose requirements.
  • With our new facility, Avirmax CMC Inc. is able to deliver high yield and quality vectors efficiently, timely and cost effectively.

Global Jetting SUB Market Report 2022: Rising Demand for the Efficient Extraction of Oil & Gases from Reservoirs and Rig Pipe Handling Systems Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, October 3, 2022
Other Energy, Energy, Efficiency, Research, Growth, SUB, BOP, Safety, Platform, Petroleum

The global jetting SUB market is anticipated to grow at a formidable rate during the forecast period, 2023-2027.

Key Points: 
  • The global jetting SUB market is anticipated to grow at a formidable rate during the forecast period, 2023-2027.
  • The market growth can be attributed to the rising demand for the efficient extraction of oil & gases from the reservoir and rig pipe handling system.
  • Besides, high demand for oil & gas from various end-user industries is expected to boost the market growth.
  • Jetting SUB is a flushing jet device that dislodges debris by jetting the BOP ram cavities, annular, and wellhead.